9.50Open9.50Pre Close0 Volume1 Open Interest15.00Strike Price0.00Turnover630.82%IV10.99%PremiumDec 20, 2024Expiry Date7.08Intrinsic Value100Multiplier0DDays to Expiry2.43Extrinsic Value100Contract SizeAmericanOptions Type0.9399Delta0.0198Gamma3.04Leverage Ratio-0.5139Theta0.0003Rho2.86Eff Leverage0.0011Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet